

Cicor Technologies Ltd. Investora 2023

September 13, 2023

Alexander Hagemann (CEO)

Peter Neumann (CFO)

The information in this presentation does not constitute an offer or invitation and may not be construed as a recommendation by us to purchase, hold or sell shares of Cicor Technologies Ltd.

This information or any copy thereof may not be sent or taken to or distributed in any jurisdiction in which such transmission or distribution is unlawful. This document may contain certain 'forward-looking' statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Actual outcomes and results may differ materially from any outcomes or results expressed or implied by such forwardlooking statements.



Alexander Hagemann

The Cicor Group

The Cicor Group - Facts and figures

Hightech Electronics Solution Provider

15

Production sites, resilient setup in Europe and Asia

2,500

Cicor employees

Sales to strategic target markets

84%

Industrial, Medical, Aerospace & Defence

EBITDA margin 1HY23

10.7% (+120bp)

Sales growth 1HY23


26% to CHF 199m

Organic growth of 9.5% Sales 2023E CHF 380-410m

Market position Europe (EMS)


No 9, goal top 3

In Cicor's core markets



Ubiquitos highend electronic components

Cicor "inside" in three core markets



Industrial Development and production of complex solutions for industrial electronics.




Medical

Advanced medical devices combining increasingly sophisticated functions in the smallest possible space.

Aerospace & Defence


Highly reliable equipment for mission and life-critical applications.

Revenue split by target market



Cicor core markets

Industrial - Tiny things make big things run smoothly









Important role in improving efficiency of industry

Digital transformation, IoT, increasing automation and smart cities require sensors whose electronic parts are becoming increasingly complex and miniaturized. With the help of electronics in the robots, they can perform even more sophisticated work and tasks.


In the energy sector, electronic control systems ensure an optimal energy supply and maximum safety.

Application examples

- Temperature control systems
- Control units for energy sector
- Camera sensors
- Control and regulation systems
- Building technologies

Cicor core markets

Medical Technology – A focus of our eyes and ears









For global healthcare

Medical technology is critical to improving global healthcare. At Cicor, we have been developing and producing highly complex medical devices for decades, combining increasingly sophisticated functions. Our product and test development with integrated quality assurance, manufacturing processes specialized in medical technology and pharmaceutical applications, and assembly of electronics and precision plastics guarantee the highest standards in terms of safety and reliability.

Application examples

- Hearing aids and cochlear implants
- Pacemakers and defibrillators
- Medical imaging
- Drug delivery systems
- Lung respiratory devices
- Defibrillators
- Shock wave therapy devices

Cicor core markets

Aerospace & Defence – The space is Cicor's limit









Satellites and Mars robots operate with Cicor parts

Operationally relevant Cicor parts are in remotecontrolled Mars robots and other space market products. Overall, 50 percent of satellites operate with Cicor solutions.

Highly reliable equipment is critical for mission and lifecritical applications. For over 30 years, we have supported strategic international programs and partnered with market-leading prime and tier-one companies.

Application examples


- Communication modules for satellites
- T/R modules
- Camera systems for Mars robots
- High frequency modules
- Cables
- High-end aerospace electronics

Cicor's complete service offering

From design to finished product

Maintenance Modification Repair Services Refurbishment Obsolescence Management

Electronic Manufacturing Services Precision Plastics Hybrid Circuits Printed Circuit Boards Printed Electronics



Product Development Hard- and Software Engineering Mechanical Design Test Development Redesign

> New Product Introduction Procurement Test Concepts Prototyping Validation

Global footprint

Solution power close to customers and operational excellence





Alexander Hagemann



A good market to be in

European EMS market with inherent structural growth



Source: Weiss Engineering (in4ma) September 8, 2023

Megatrends drive momentum – 8-10% organic growth of addressable market

Electronics market growth driven by automation, connectivity and electrification*

OEM focus on core competencies and **outsource** development and production**


Near- / reshoring trend – Clients looking for alternatives to China

~ 5% CAGR + ~ 2% CAGR + ~ 1 - 3% CAGR ~ 8 - 10 % CAGR

* Volume growth in USD. Source: New Venture Research Corporation, 2022; ** Outsourcing expected to rise from 36% to 39% 2021 – 2026 - share of electronics manufactured by EMS. Source: New Venture Research Corp., 2022


Positioned in the most attractive segment of electronics manufacturing

Cicor operates in the sweet-spot of scale at attractive margins



Annual sales in USD

Cicor is well positioned to benefit from megatrends



Cicor strategy

A strong platform for organic growth and industry consolidation



Focus on our three **core markets** with highly profitable high-mix/low-volume businesses



Strategic customer relationships through excellent solution finding, differentiated technology portfolio and flawless execution



Active consolidation through **M&A**

Multi-regional strategy

Making Cicor a European leader one country at a time

- Replicating the proven business model by acquiring highly focused and profitable EMS in UK and Germany:
 - Axis Electronics (11/2021) is the leader in aerospace
 & defense in the UK
 - SMT Elektronik (04/2022) and Phoenix Mecano Digital Electronic (01/2023) establish a strong position in Germany
- Significant expansion of addressed market
- Latest acquisition establishes Tunisia as another best cost country for manufacturing
- AFT Microwave carve-out (03/2023) strengthens business of hybrid substrates



Competitive landscape

Clients choose Cicor as one-stop shop for our target markets

| | Industries | | | Solutions | | | | | | | |
|----------------|------------|------------|-----|------------|-------------------------|-----|-----------------------|-----------|--------------------|-----|------------------------|
| | Medical | Industrial | A&D | Automotive | Engineering Services | EMS | Precision Plastics | Metalwork | Hybrid Circuits | PCB | Printed Electronics |
| cicor | • | • | • | | • | • | ٠ | | • | • | • |
| <u>zaliner</u> | • | • | • | • | • | • | | • | | | |
| GPV | • | • | | | • | • | | | | | |
| Kitron | • | • | • | • | • | • | | | | | |
| ΗΛΝΖΛ | • | • | • | • | • | • | | • | | | |
| | • | • | | ٠ | • | • | | | | | |
| KATEK | • | • | | • | • | • | | | | | |




Peter Neumann

Financial Results 1HY2023


Long-term view – Impact of Cicor growth strategy

Performance 2018 – 2023



- Cicor achieves best half-year results ever in terms of sales and EBITDA, demonstrating the success of its growth strategy
- Organic¹⁾ sales growth of 9.5%
- Profitable growth with 10% Sales CAGR and 13% EBITDA CAGR over the last five years


Record sales and core results from organic growth and acquisitions Key figures H1/2023



1) Before amortization of goodwill and intangible assets from acquisitions TCHF 4 677 (2022: TCHF 4 512). Adjusted for related income tax effects of TCHF -345 (2022: TCHF -376) for Core net profit.

Performance 2018 – 2023

Profitable growth in EMS Division



RHe was newly allocated from AS into EMS as from 2021, prior years are not restated.

Sales H2 Sales H1 🔶 EBITDA margin in %

1HY23 P&L with record high in net sales and EBITDA


Consolidated Income Statement in TCHF

| | HY 23 | in % | HY 22 | in % | %YoY |
|--|----------|-------|---------|-------|-------|
| Net sales | 199 152 | 100.0 | 157 747 | 100.0 | 26.2 |
| Material expenses | -109 443 | -55.0 | -85 785 | -54.4 | 27.6 |
| Operating expenses | -68 373 | -34.3 | -56 933 | -36.1 | 20.1 |
| EBITDA | 21 336 | 10.7 | 15 029 | 9.5 | 42.0 |
| Depreciation and amortization | -6 121 | -3.1 | -5 366 | -3.4 | 14.1 |
| Amortization of M&A Goodwill and intang. | -4 677 | -2.3 | -4 512 | -2.9 | 3.7 |
| EBIT | 10 538 | 5.3 | 5 151 | 3.3 | 104.6 |
| Financial result | -2 599 | -1.3 | -2 694 | -1.7 | - 3.5 |
| Income taxes | -3 045 | -1.5 | -1 645 | -1.0 | 85.1 |
| Net profit | 4 894 | 2.5 | 812 | 0.5 | 502.7 |
| Core EBIT | 15 215 | 7.6 | 9 663 | 6.1 | 57.5 |
| Core net profit | 9 226 | 4.6 | 4 948 | 3.1 | 86.5 |

- Record high in Net sales and EBITDA
- Strong contribution from EMS division results in increased EBITDA margin of 10.7%
- Financial result affected by negative currency effects in both periods
- High M&A-related goodwill and intangibles amortization charges are excluded from core results
- Core EBIT margin increased to 7.6% driven by improved operating profitability

Sales contribution – strong EMS division

HY 2023 in CHF million



- Strong organic sales growth (11.1%) in EMS division and good contribution from newly acquired companies
- Negative currency impact of -3.4% (CHF -5.3 mio) mainly due to the devaluation of GBP, RON and EUR vs. CHF
- Organic growth includes a decrease in broker sales (low margin sales), this understates EMS organic growth

Balance sheet supports further growth

Consolidated Balance Sheet in TCHF

| | Jun 2023 | in % | Dec 2022 | in % |
|---|-------------|-------|-------------|-------|
| | | | | |
| Current assets | 286'407 | 70.8 | 251'422 | 68.6 |
| Non-current assets | 118'286 | 29.2 | 115'313 | 31.4 |
| Total Assets | 404'693 | 100.0 | 366'735 | 100.0 |
| Current liabilities | 126'267 | 31.2 | 102'829 | 28.0 |
| Non-current liabilities | 124'630 | 30.8 | 115'015 | 31.4 |
| Equity | 153'796 | 38.0 | 148'891 | 40.6 |
| Total Liabilities and equity | 404'693 | 100.0 | 366'735 | 100.0 |
| | | | | |
| Net Debt | 62'958 | | 44'522 | |
| Gearing ratio (net debt in % of equity) | 40.9 | | 29.9 | |
| Net debt / EBITDA LTM | 1.63 | | 1.38 | |
| Net debt / EBITDA LTM proforma 1) | 1.55 | | 1.36 | |
| Equity Ratio | 38.0% | | 40.6% | |

1) Acquisitions are included for twelve months pro forma as defined in the covenants agreed with the banking syndicate.

- Net debt of CHF 63.0 million increased by CHF 18.4 million, CHF 22.0 million was used for the acquisition of businesses
- Total debt CHF 127.1 mn with CHF 15.6 million being short-term
- Net debt/EBITDA 1.55x (Dec. 22: 1.36x) Equity ratio 38.0% (Dec. 22: 40.6%)
- All bank covenants are met as of June 2023 (equity ratio > 30.0% and leverage net debt / EBITDA < 2.75 including acquisition pro forma)


Positive cash flow from operating activities

Consolidated Cash Flow Statement in TCHF

| | HY 23 | HY 22 |
|---|---------|---------|
| Net profit | 4 894 | 812 |
| Depreciation, amortization and impairment | 10 798 | 9 878 |
| Other non cash items | 2 597 | 696 |
| Changes in working capital | -7 421 | -28 101 |
| Net cash from / (used in) operating activities | 10 868 | -16 715 |
| Purchase of Property, plant and equipment (net) | -5 433 | -4 956 |
| Purchase of intangible assets | - 204 | - 133 |
| Acquisition of subsidiaries, net of cash acquired | -21 985 | -13 984 |
| Net cash used in investing activities | -27 622 | -19 073 |
| Free cash flow | -16 754 | -35 788 |
| Free Cash Flow excl. acquisitions | 5 231 | -21 804 |
| Net cash from financing activities | 5 545 | 5 704 |
| Currency translation effects | - 113 | - 550 |
| Cash flow | -11 322 | -30 634 |

- Positive cash flow from operating activities (CHF 10.9 mn, 1H22 CHF –16.7 mn) driven by strong net income performance and focus on working capital management
- Operating Net Working capital (ONWC) stabilized at a high level (35% of last twelve months of revenue).
- With supply chain normalization, objective is to get back to historic levels of 25-30% mid-term.
- Positive free cash flow before acquisitions (CHF 5.2 mn) demonstrates value creation of Cicor's core business

Return on Invested Capital ROIC



- ROIC in the first half of 2023 well above Cicor's weighted average cost of capital
- Increase in ROIC due to strong Core EBIT contribution in the last twelve months
- Increase in ROIC compared to prior period as adjusted core EBIT increased 68% while average net invested capital increased only 32%

ROIC in % = Core EBIT (12m rolling) / Average Net Invested Capital (12m rolling) Average Net Invested Capital (12m rolling) = Equity plus Financial liabilities minus Intangible assets out of business combinations

Core Earnings per share increase thanks to good operating profitability Key Figures per Share HY 2023 / HY 2022

| | | HY 23 | HY 22 | Change % |
|---|--------|-----------|-----------|----------|
| | | | | |
| Number of registered shares issued | 30.6. | 3 411 169 | 3 409 542 | +0.0% |
| Number of Treasury shares | 30.6. | - 251 267 | - 340 073 | -26.1% |
| Number of outstanding registered shares | 30.6. | 3 159 902 | 3 069 469 | +2.9% |
| Number of conditional shares for MCN | 30.6. | 1 267 116 | 421 052 | +200.9% |
| Number of outs. and cond. MCN shares | 30.6. | 4 427 018 | 3 490 521 | +26.8% |
| Average number of outst. and cond. MCN shares | period | 4 429 695 | 3 460 189 | +28.0% |
| | | | | |
| Core Net profit (in TCHF) | period | 9 226 | 4 948 | +86.5% |
| Core Earnings per share (in CHF) | period | 2.08 | 1.43 | +45.6% |
| | | | | |
| Share price (in CHF) | 30.6. | 43.00 | 45.70 | -5.9% |
| Market capitalization (in TCHF) | 30.6. | 190 362 | 159 517 | +19.3% |

- Number of Treasury shares reduced in H2/2022 for settlement of an M+A related earn-out liability
- The conversion of the MCN will result in 1,267,116 additional shares until 2027. These shares are considered outstanding for both EPS and market capitalization purposes
- Increase in average number of outstanding and conditional MCN shares from the issuance of the second tranche of MCNs in October 2022
- Core Earnings per share increase driven by strong operating profitability

Value accretive acquisitions

Two acquisitions successfully completed in the first half of 2023

| | HY 2023 |
|---|---------|
| | |
| Cash paid | 24 866 |
| Direct costs related to acquisition | 578 |
| Purchase consideration cash | 25 444 |
| less: Fair value of net assets acquired | -24 570 |
| Goodwill | 874 |
| | |
| Non-current Assets | 8 089 |
| Current Assets | 24 349 |
| Non current liabilities | -450 |
| Current liabilities | -7 418 |
| Total fair value of net assets acquired | 24 570 |
| | |
| Purchase consideration cash | 25 444 |
| less: cash and cash equivalents acquired | -3 459 |
| Cash outflow on acquisition during the year | 21 985 |

Cicor Digital Elektronik

- Two sites in Thuringia (Germany) and one site in Borj-Cedria (Tunisia)
- Closing of share deal in January 2023 for a consideration of TCHF 23 919, resulting in a (preliminary) Goodwill of TCHF 662
- Integrated in Cicor's EMS division

AFT Microwave

- Cicor acquired the thin-film business of AFT microwave GmbH, Backnang (Germany), as part of an asset deal
- Closing of deal in March 2023 for a consideration of TCHF 1 525, resulting in a (preliminary) Goodwill of TCHF 212
- Integrated into Reinhardt Microtech GmbH, Ulm (Germany), which is part of the Cicor AS division



Alexander Hagemann
Outlook 2023

Outlook 2023

Continued growth expected in 2023 despite challenging environment

- The continued growth momentum in order intake and sales leads to higher expectations than previously communicated (If the geopolitical, economic and financial environment does not deteriorate further)
- Expect 2023 sales of CHF 380 410 million (previous guidance: CHF 360 400 million)
- Operating result (EBITDA) forecasted at CHF 40 – 45 million (previous guidance: Comparable EBITDA margin to 2022 which stood at 10.3%)



Reasons to invest

Cicor – an asset for your portfolio

- Market with resilient growth and current tailwinds, outsourcing' and nearshoring'
- Strategy targeting the profitable segments of the market: Industrial, Medical Technology, Aerospace & Defence
- Value accretive buy and build ambition with disciplined approach and clear targets
- Management with track-record for successful organic and inorganic growth



Cicor Technologies Ltd.

Analysts

Kepler Cheuvreux

Patrick Steiner psteiner@keplercheuvreux.com +43 (1) 20 577 383

Research Partners AG

Reto Huber reto.huber@researchpartners.ch +41 44 533 40 30

Zürcher Kantonalbank

Bernd Laux bernd.laux@zkb.ch +41 44 292 37 23

Baader Helvea

Emrah Basic ebasic@helvea.com +41 43 388 92 50

Alster Research

Graeme Davies g.davies@alsterresearch.com +49 40 309 293 52

Investor Relations

Agenda 2023

| October 16 | Business Update Q3/2023 |
|------------|--|
| December 4 | Cicor Capital Markets Event 2023, Zurich (Switzerland) |

| September 13 | Investora 2023, Zurich (Switzerland) |
|----------------|---|
| November 27-29 | Deutsches Eigenkapitalforum 2023, Frankfurt (Germany) |



Investor Relations

Contacts





Alexander Hagemann CEO Peter Neumann CFO



Michael Götti VP Corporate Marketing & Communications

Cicor Management AG, Gebenloostrasse 15, 9552 Bronschhofen, Switzerland investor@cicor.com | +41 71 913 73 00



Thank You



cicor.com

Cicor Group

in

© @cicorgroup